

Bristol-Myers Squibb response re alleged advocacy campaign by Innovative Pharmaceutical Association of South Africa (IPASA) opposing South Africa's efforts to introduce intellectual property reforms aimed at increasing access to essential medicine:

19 February 2014

Business & Human Rights Resource Centre invited Bristol-Myers Squibb to respond to the following items:

- "South African pharma firms accused of delaying patents law reforms", Guardian [UK], 17 January 2014
<http://www.theguardian.com/world/2014/jan/17/south-african-pharma-accused-delay-patents-law-reform>
- "New leaked Merck missive reveals deep drug, medical device company opposition to South African patent reforms", KEI, 20 January 2014
<http://keionline.org/node/1908>
- "'Genocidal' drug patent plot angers doctors, rights groups"
<http://www.timeslive.co.za/politics/2014/01/17/genocidal-drug-patent-plot-outrages-doctors-rights-groups>
- "Leaked pharmagate emails prove big pharma involvement in scandal"
<http://www.tac.org.za/news/leaked-pharmagate-emails-prove-big-pharma-involvement-scandal>
- "TAC, Section27 and MSF react to Pharmagate"
<http://www.fixthepatentlaws.org/?p=823>

Comment to Business & Human Rights Resource Centre by Bristol-Myers Squibb re alleged advocacy campaign by Innovative Pharmaceutical Association of South Africa (IPASA) to oppose South Africa's efforts to introduce intellectual property reforms aimed at increasing access to essential medicine:

Thank you for reaching out to Bristol-Myers Squibb individually on this topic but we refer any specific questions concerning South Africa's patent policy to IPASA.